KR20130120993A - 글루코키나아제 활성화제로서의 3-옥소-3,9-다이하이드로-1h-크로메노[2,3-c]피롤 - Google Patents

글루코키나아제 활성화제로서의 3-옥소-3,9-다이하이드로-1h-크로메노[2,3-c]피롤 Download PDF

Info

Publication number
KR20130120993A
KR20130120993A KR1020127032727A KR20127032727A KR20130120993A KR 20130120993 A KR20130120993 A KR 20130120993A KR 1020127032727 A KR1020127032727 A KR 1020127032727A KR 20127032727 A KR20127032727 A KR 20127032727A KR 20130120993 A KR20130120993 A KR 20130120993A
Authority
KR
South Korea
Prior art keywords
oxo
dihydro
chromeno
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127032727A
Other languages
English (en)
Korean (ko)
Inventor
라마칸쓰 사라부
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20130120993A publication Critical patent/KR20130120993A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127032727A 2010-06-17 2011-06-14 글루코키나아제 활성화제로서의 3-옥소-3,9-다이하이드로-1h-크로메노[2,3-c]피롤 Ceased KR20130120993A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35561910P 2010-06-17 2010-06-17
US61/355,619 2010-06-17
PCT/EP2011/059783 WO2011157682A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Publications (1)

Publication Number Publication Date
KR20130120993A true KR20130120993A (ko) 2013-11-05

Family

ID=44266428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032727A Ceased KR20130120993A (ko) 2010-06-17 2011-06-14 글루코키나아제 활성화제로서의 3-옥소-3,9-다이하이드로-1h-크로메노[2,3-c]피롤

Country Status (10)

Country Link
US (1) US8178689B2 (enExample)
EP (1) EP2582706A1 (enExample)
JP (1) JP5844355B2 (enExample)
KR (1) KR20130120993A (enExample)
CN (1) CN102947311B (enExample)
BR (1) BR112012032235A2 (enExample)
CA (1) CA2801168A1 (enExample)
MX (1) MX2012010668A (enExample)
RU (1) RU2603191C2 (enExample)
WO (1) WO2011157682A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2938609T3 (pl) * 2012-12-25 2017-08-31 Hua Medicine Sposób wytwarzania 1-([1,3]dioksolan-4-ylometylo)-1h-pirazol-3- iloaminy
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2020083855A1 (en) * 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Novel tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease
CN113493442B (zh) * 2020-04-03 2024-11-08 天津药物研究院有限公司 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK496784A (da) 1983-10-18 1985-04-19 Du Pont 8-substituerede pyrazolopentathiepiner og dermed beslaegtede forbindelser
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
JPH0477477A (ja) 1990-07-18 1992-03-11 Takeda Chem Ind Ltd チアジアゾール酢酸誘導体の製造法
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL103678A (en) 1991-11-13 1996-09-12 Schering Ag History of pyrazolylpyrazole, processes for their preparation and herbicidal preparations containing them
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
AU768539B2 (en) 1998-04-30 2003-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, their preparation and use
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
AU777735B2 (en) 1999-07-15 2004-10-28 Pharmacopeia, Inc. Bradykinin B1 receptor antagonists
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003095438A1 (en) 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
WO2004033462A2 (en) 2002-10-09 2004-04-22 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
AU2004220234C1 (en) 2003-02-13 2013-01-17 Msd K.K. Novel 2-pyridinecarboxamide derivatives
UA81468C2 (en) 2003-02-26 2008-01-10 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives
JP4769192B2 (ja) 2003-10-24 2011-09-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規な化合物及び組成物
UA81365C2 (en) 2003-10-27 2007-12-25 Merck & Co Inc Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US20080312207A1 (en) 2004-02-18 2008-12-18 Craig Johnstone Compounds
US20080293722A1 (en) 2004-03-16 2008-11-27 Wyeth Ion Channel Modulators
WO2005090332A1 (ja) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd 置換キナゾリン又はピリドピリミジン誘導体
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
BRPI0613591A2 (pt) 2005-07-08 2011-01-18 Novo Nordisk As ativadores de dicicloalquil uréia glicocinase
TWI359149B (en) 2005-07-11 2012-03-01 Mitsubishi Tanabe Pharma Corp An oxime derivative and preparations thereof
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
BRPI0615236A2 (pt) 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP2009513704A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
CA2637172A1 (en) 2006-01-27 2007-08-09 Array Biopharma Inc. Pyridin-2-amine derivatives and their use as glucokinase activators
CN101437816B (zh) 2006-03-24 2013-08-14 阿雷生物药品公司 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
WO2008111473A1 (ja) 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators

Also Published As

Publication number Publication date
JP5844355B2 (ja) 2016-01-13
MX2012010668A (es) 2012-10-03
CA2801168A1 (en) 2011-12-22
BR112012032235A2 (pt) 2019-09-24
US20110313002A1 (en) 2011-12-22
WO2011157682A1 (en) 2011-12-22
EP2582706A1 (en) 2013-04-24
US8178689B2 (en) 2012-05-15
CN102947311B (zh) 2015-11-25
RU2012156706A (ru) 2014-07-27
JP2013532146A (ja) 2013-08-15
RU2603191C2 (ru) 2016-11-27
CN102947311A (zh) 2013-02-27
HK1178532A1 (zh) 2013-09-13

Similar Documents

Publication Publication Date Title
KR101259249B1 (ko) 피롤리딘온 글루코키나제 활성화제
JP5301655B2 (ja) ピリダジノングルコキナーゼアクチベーター
US11254663B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
AU2014352008B2 (en) Tricyclic piperidine compounds
JP5844355B2 (ja) グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール
US20130131113A1 (en) Pyridone glucokinase activators
HK1178532B (en) 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
US20120142705A1 (en) Isatin and oxindole compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160613

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170519

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170519

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I